Natural History Study in Pediatric Patients With MYBPC3 Mutation-associated Cardiomyopathy (MyCLIMB)
A Prospective and Retrospective Registry and Biomarker Study to Evaluate the Natural History of Pediatric Patients With Cardiomyopathy Due to MYBPC3 Mutations
Sponsor: Tenaya Therapeutics
This observational or N/A phase trial investigates Cardiomyopathy and is currently actively recruiting participants. Tenaya Therapeutics leads this study, which shows 17 recorded versions since 2021 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
17 versions recorded-
Sep 2025 — Present [monthly]
Recruiting
-
Dec 2024 — Sep 2025 [monthly]
Recruiting
-
Sep 2024 — Dec 2024 [monthly]
Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Recruiting
-
Dec 2023 — Jul 2024 [monthly]
Recruiting
▶ Show 12 earlier versions
-
Nov 2023 — Dec 2023 [monthly]
Recruiting
-
Sep 2023 — Nov 2023 [monthly]
Recruiting
-
Aug 2023 — Sep 2023 [monthly]
Recruiting
-
Mar 2023 — Aug 2023 [monthly]
Recruiting
-
Dec 2022 — Mar 2023 [monthly]
Recruiting
-
Sep 2022 — Dec 2022 [monthly]
Recruiting
-
May 2022 — Sep 2022 [monthly]
Recruiting
-
Apr 2022 — May 2022 [monthly]
Recruiting
-
Mar 2022 — Apr 2022 [monthly]
Recruiting
-
Feb 2022 — Mar 2022 [monthly]
Recruiting
-
Jan 2022 — Feb 2022 [monthly]
Recruiting
-
Dec 2021 — Jan 2022 [monthly]
Recruiting
First recorded
Nov 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Tenaya Therapeutics
For direct contact, visit the study record on ClinicalTrials.gov .